Learning Objectives:

  • Selective pressure from targeted therapy drives clonal evolution of CLL
  • Double-refractory and double-exposed CLL have distinct disease characteristics and outcome
  • Clinical trials are testing novel treatment strategies in relapsed/refractory CLL
Session date: 
09/16/2024 - 12:00pm to 1:00pm CDT
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Please login or create an account to proceed.
Speaker Name: 
Inhye Ahn, MD